TSB has spoken to a few analysts, who are not as high on the company succeeding as some of the better known names in our industry. In addition, there have been recent reports of "pilot error" in implanting this device. So fasten your seat belts and sit back, let's see what one of the company's that has been projected as an up and comer has to say this week. TSB wants to know what our readers think?
Monday, October 26, 2009
This Week in Spine.
On Thursday, October 29th, Trans1 will be releasing its QIII results. TSB speculates that the number will not fall as short as expected. The major problem that looms as an obstacle continues to be reimbursement. Even though the company is addressing this from an educational standpoint, they still have a bit of a road to travel.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment